We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Malarone (atovaquone; proguanil hydrochloride) Tablet

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Malarone (atovaquone; proguanil hydrochloride) Tablet

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Malarone is a fixed-dose combination of atovaquone and proguanil hydrochloride, antimalarial agents, in tablet formulation for prescription use only. Malarone comes in both adult and pediatric dosage tablets. The adult tablets contain 250mg of atovaquone and 100mg of proguanil hydrochloride, while the pediatric tablets contain 62.5mg of atovaquone and 25mg of proguanil hydrochloride.

    Clinical Results

    Three phase II clinical studies were conducted, one testing atovaquone alone, one testing proguanil hydrochloride alone and one testing the combination, for the treatment of acute, uncomplicated malaria. Malarone was tested in eight phase III controlled clinical trials for the same indication. 471 patients were treated with the equivalent of four Malarone tablets once daily for three days. 464 had a sensitive response (the elimination of parasitemia with no recurrent sign of parasitemia for up to 28 days) and seven patients had R1 resistance (the elimination of parasitemia, but with recurrence between 7 and 28 days following treatment). Treatment with Malarone was comparable with treatment with a comparator drug in four of the studies and better than treatment with a comparator drug in the other four studies. The overall efficacy in 521 patients was 98.7%.

    To see more clinical results for earlier studies go to Glaxo Wellcome

    Side Effects

    Side effects which may occur in adult patients include, but are not limited to:

    • abdominal pain
    • nausea
    • vomiting
    • headache
    • diarrhea
    • asthenia
    • dizziness
    • anorexia

    Treatment was discontinued prematurely due to side effects in only four of 436 adults. Greater occurrence of adverse effects were found with higher dosages of Malarone.

    Side effects which may occur in pediatric patients include, but are not limited to:

    • nausea
    • vomiting
    • pruritus

    Treatment was discontinued prematurely due to side effects in one of 116 pediatric patients.

    Malarone is contraindicated for all patients who have a history of hypersensitivity to atovaquone or proguanil hydrochloride. During clinical trials only one case of anaphylaxis was observed due to treatment with Malarone.

    Patients should know that drug interactions occur with tetracycline, metoclopramide and rifampin, decreasing the effectiveness of Malarone.

    While no conclusive studies have been done on humans related to pregnancy and the effects of Malarone, certain adverse effects were seen on the fetuses of rabbits and rats treated with Malarone and its components. Pregnant mothers should only take Malarone if the benefit from the drug equals or surpasses the risk to the fetus. It is also not known if Malarone is secreted in the milk of nursing mothers. Proguanil hydrochloride was found in the milk of rabbits and rats treated with the drug. It is not known if atovaquone is found in the milk of test animals treated with the drug.

    Mechanism of Action

    The constituents of Malarone, atovaquone and proguanil hydrochloride, interfere with two different pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. Atovaquone is a selective inhibitor of parasite mitochondrial electron transport. Proguanil hydrochloride primarily exerts its effect by means of the metabolite cycloguanil, a dihydrofolate reductase inhibitor. Inhibition of dihydrofolate reductase in the malaria parasite disrupts deoxythymidylate synthesis. (From FDA Label)

    Additional Information

    For additional information about Malarone go to: Glaxo Wellcome

    Approval Date: 2000-07-01
    Date Created: 2000-10-05 12:00:00
    Company Name: GlaxoSmithKline
    Back to Listings

    Upcoming Events

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    • China-360x240

      U.S. Tops List of Trial Startups With China Making Progress in Phase 1

    • Phoneapp-360x240

      Device Apps Present Unique Risks in Trials

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing